How to launch a UK ED telehealth service in 2026: the regulatory and operational brief

Launching a UK ED (erectile dysfunction) telehealth service in 2026 requires a clinical pathway that includes proper cardiovascular and medication-interaction screening, a dispensing operation that handles the licensed PDE5 inhibitors and other treatments, and marketing that stays within UK rules on POM advertising. ED is one of the most established telehealth categories in the UK — the operational template is well-defined, and the regulatory expectations are firm. This piece is the launch brief.

Why ED is a foundational telehealth category in the UK

ED telehealth has been operating in the UK since the early 2010s and has a well-established clinical and dispensing pattern. Patient demand is consistent. Licensed treatments (sildenafil, tadalafil, vardenafil, alprostadil) have predictable supply chains. Remote prescribing suits the privacy-sensitive nature of the consultation. The category is mature — which means the bar for new entrants is set by mature operators, not by greenfield expectations.

Clinical screening — cardiovascular risk, medication interactions, contraindications

ED is often the first presentation of an underlying cardiovascular issue. The clinical screening must cover: cardiovascular history, current medications (especially nitrates — absolute contraindication with PDE5 inhibitors), blood pressure, blood sugar, and broader sexual health context. Inadequate screening is not just a clinical risk; it is the enforcement pattern that has caught operators in this category across multiple inspections.

The product mix — generics, brands, alternative formulations

Licensed UK ED treatments include generic sildenafil and tadalafil (most prescribed) and branded equivalents, plus alprostadil for patients where PDE5 inhibitors are unsuitable. Brands typically launch with the generic catalogue first, expanding to branded variants based on patient preference. Daily-dose tadalafil is a distinct product line with its own clinical considerations and prescribing pattern.

Patient pathway — consultation, prescribing, ongoing supply

Standard ED patient pathways: initial consultation with full medical history and ED-specific questions, clinical decision and prescribing, ongoing supply on repeat with periodic review. Periodic review (typically annual at minimum) should reassess cardiovascular health, medication review, and ED control. A pathway that auto-refills without review is not defensible at inspection.

Regulatory posture and advertising constraints

ED prescribing sits under standard regulators (GPhC, MHRA, CQC, ICO). The category-specific watch point is advertising. Prescription-only medicines cannot be advertised to the public — ASA and MHRA enforce strictly on ED brands naming medicines, suggesting brand specificity, or making efficacy claims. Marketing the service is legitimate; marketing the medicine is not. ED brands have been notable enforcement targets.

How PExpo supports ED brand launches

PExpo's brand model includes the clinical workflow, UK prescriber network, GPhC-compliant dispensing of the ED product range, and the integrations a patient pathway needs. The brand operates patient-facing; PExpo operates the regulated layers behind it. See our brand model page for the full scope or our clinic model page if you are an existing clinic adding ED.

ED telehealth is a mature category. The bar for new entrants is set by mature operators, not by greenfield expectations.

Launching a UK ED telehealth service in 2026 is well-mapped territory. The operators who build proper clinical screening, stay within POM advertising rules, and design ongoing review into the patient pathway compound. The ones who optimise for fast checkout without proper screening absorb the enforcement attention. See our brand model page for the white-label launch route or our clinic model page for ED inside an existing clinic.

Frequently asked questions